

Su-Pin Choo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6666473/publications.pdf>

Version: 2024-02-01

93
papers

8,707
citations

126858

33
h-index

48277

88
g-index

97
all docs

97
docs citations

97
times ranked

11166
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	6.3	3,224
2	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 1116-1135.	7.7	637
3	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2022, 23, 77-90.	5.1	526
4	SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1913-1921.	0.8	467
5	Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. <i>Nature Genetics</i> , 2013, 45, 1474-1478.	9.4	426
6	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	1.8	310
7	Comparison of hepatocellular carcinoma in eastern versus western populations. <i>Cancer</i> , 2016, 122, 3430-3446.	2.0	221
8	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	1.8	180
9	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020, 9, 245-260.	4.2	172
10	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	7.7	157
11	RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1371-1380.	1.6	128
12	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 600-609.	1.8	127
13	Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2673-2683.	1.6	118
14	The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. <i>Nature Communications</i> , 2017, 8, 4565.	5.8	117
15	A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. <i>Hpb</i> , 2016, 18, 7-12.	0.1	95
16	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in <i>Opisthorchis viverrini</i> Associated Cholangiocarcinoma. <i>EBioMedicine</i> , 2016, 8, 195-202.	2.7	94
17	AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). <i>Journal of Hepatology</i> , 2010, 52, 79-87.	1.8	88
18	Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. <i>Frontiers in Immunology</i> , 2020, 11, 568759.	2.2	79

#	ARTICLE	IF	CITATIONS
19	Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome. <i>JAMA Oncology</i> , 2017, 3, 1538.	3.4	72
20	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70
21	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	3.2	63
22	Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. <i>Scientific Reports</i> , 2017, 7, 40737.	1.6	62
23	Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e90909.	1.1	59
24	Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1025-1035.	3.7	56
25	Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2019, 10, 2093.	2.2	51
26	Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 595-601.	1.8	50
27	A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). <i>Annals of Oncology</i> , 2016, 27, 2210-2215.	0.6	48
28	National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2016, 5, 97-106.	4.2	47
29	The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0118658.	1.1	46
30	Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 683-694.	1.8	45
31	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988900.	1.4	44
32	Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2014, 8, 395-404.	1.9	41
33	Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling. <i>European Radiology</i> , 2009, 19, 1184-1196.	2.3	36
34	Identification of Serum Monocyte Chemoattractant Protein-1 and Prolactin as Potential Tumor Markers in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e68904.	1.1	36
35	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. <i>JCO Global Oncology</i> , 2020, 6, 628-638.	0.8	35
36	Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2009, 16, 267-279.	1.6	33

#	ARTICLE	IF	CITATIONS
37	Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. <i>Immunotherapy</i> , 2019, 11, 167-175.	1.0	33
38	Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 397-408.	1.1	32
39	Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. <i>World Journal of Hepatology</i> , 2018, 10, 433-447.	0.8	31
40	PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. <i>Nature Communications</i> , 2019, 10, 2484.	5.8	30
41	<i>Coriolus versicolor</i> (<i>Yunzhi</i>) Use as Therapy in Advanced Hepatocellular Carcinoma Patients with Poor Liver Function or Who Are Unfit for Standard Therapy. <i>Journal of Alternative and Complementary Medicine</i> , 2017, 23, 648-652.	2.1	29
42	Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 9-21.	4.2	29
43	Gastric peritoneal carcinomatosis - a retrospective review. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 121.	0.8	27
44	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
45	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2022, 71, 1277-1288.	6.1	23
46	Electroacupuncture for Refractory Acute Emesis Caused by Chemotherapy. <i>Journal of Alternative and Complementary Medicine</i> , 2006, 12, 963-969.	2.1	21
47	Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafenib in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. <i>BMC Cancer</i> , 2016, 16, 856.	1.1	20
48	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5272-5281.	3.2	20
49	201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. <i>International Journal of Hyperthermia</i> , 2017, 33, 288-294.	1.1	19
50	Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e249-e261.	0.7	18
51	Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbidities. <i>Molecular and Clinical Oncology</i> , 2013, 1, 190-194.	0.4	17
52	Cancer Supportive and Survivorship Care in Singapore: Current Challenges and Future Outlook. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	17
53	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	17
54	Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. <i>World Journal of Gastroenterology</i> , 2010, 16, 3709.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Breast Lymphoma: Favorable Prognosis after Treatment with Standard Combination Chemotherapy. <i>Oncology Research and Treatment</i> , 2006, 29, 14-18.	0.8	15
56	Gastrointestinal stromal tumour in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 256-261.	2.0	14
57	Metastatic gastric cancer: Does the site of metastasis make a difference?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 10-17.	0.7	14
58	Activity of Thalidomide and Capecitabine in Patients With Advanced Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 222-227.	0.6	13
59	Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series. , 2019, 7, 162.		13
60	Capecitabine-induced oromandibular dystonia: A case report and literature review. <i>Acta Oncologica</i> , 2008, 47, 1161-1165.	0.8	11
61	Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. <i>Liver Cancer</i> , 2022, 11, 426-439.	4.2	11
62	Comparison of health state values derived from patients and individuals from the general population. <i>Quality of Life Research</i> , 2017, 26, 3353-3363.	1.5	10
63	Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 306-324.	1.0	9
64	Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 141-150.	1.1	8
65	Potentially Functional SNPs (pfSNPs) as Novel Genomic Predictors of 5-FU Response in Metastatic Colorectal Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e111694.	1.1	8
66	Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 275-283.	0.7	8
67	Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma. <i>Surgery</i> , 2018, 163, 1008-1013.	1.0	8
68	A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 583-590.	1.1	6
69	Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit. <i>ESMO Open</i> , 2021, 6, 100129.	2.0	6
70	The fibroblast growth factor receptor pathway in hepatocellular carcinoma. <i>Hepatoma Research</i> , 2018, 4, 52.	0.6	6
71	Hypoglycaemia in a 63-Year-Old Female with a Large, Recurrent, Metastatic Gastrointestinal Stromal Tumour (GIST). <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 263-265.	0.6	4
72	Do elderly patients benefit from enrollment into Phase I Trials?. <i>Journal of Geriatric Oncology</i> , 2015, 6, 241-248.	0.5	4

#	ARTICLE	IF	CITATIONS
73	Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 224-239.	4.2	4
74	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study – An Asian Tertiary Cancer Center Experience. <i>JCO Precision Oncology</i> , 2021, 5, 859-875.	1.5	4
75	Microarray-based tumor molecular profiling to direct choice of cisplatin plus S-1 or oxaliplatin plus S-1 for advanced gastric cancer: A multicentre, prospective, proof-of-concept phase 2 trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 48-48.	0.8	4
76	Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis. <i>Journal of Thoracic Oncology</i> , 2009, 4, 988-993.	0.5	3
77	Rapamycin and Thalidomide Treatment of a Patient with Refractory Metastatic Gastroesophageal Adenocarcinoma: A Case Report. <i>Oncologist</i> , 2010, 15, 965-968.	1.9	3
78	Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial. <i>Liver Cancer</i> , 2022, 11, 451-459.	4.2	3
79	Increased α -Fetoprotein Likely Induced by Complementary Health Products. <i>Journal of Clinical Oncology</i> , 2013, 31, e80-e82.	0.8	2
80	Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study. <i>Annals of Oncology</i> , 2017, 28, iii139.	0.6	2
81	Resected pancreatic adenocarcinoma: An Asian institution's experience. <i>Cancer Reports</i> , 2021, 4, e1393.	0.6	2
82	Letters to the editor: The not so innocuous abdominal tap. <i>Palliative Medicine</i> , 2007, 21, 62-62.	1.3	1
83	Deconvolution assessment of splenic and splanchnic contributions to portal venous blood flow in liver cirrhosis. <i>Medical Physics</i> , 2011, 38, 2768-2782.	1.6	1
84	Mucosal and Subcutaneous Metastasis from Hepatocellular Carcinoma: A Case Report. <i>Proceedings of Singapore Healthcare</i> , 2014, 23, 306-308.	0.2	1
85	Novel Targets in Advanced Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 192-198.	1.0	1
86	What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 23-27.	0.7	1
87	Responding to the rising incidence of hepatocellular carcinoma with targeted therapy. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 96-7.	0.8	1
88	Atezolizumab and bevacizumab for HCC in the real world. <i>Liver International</i> , 2022, 42, 727-728.	1.9	1
89	An Alternative Therapy for Patients with Hepatic Impairment?. <i>Oncology Research and Treatment</i> , 2007, 30, 474-475.	0.8	0
90	Hepatic artery infusion in the treatment of colorectal cancer metastases. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 106-113.	1.0	0

#	ARTICLE	IF	CITATIONS
91	SIRT-Y90 followed by gemcitabine plus cisplatin for Intra-hepatic cholangiocarcinoma: a phase II study. <i>Annals of Oncology</i> , 2015, 26, vii121.	0.6	0
92	Challenges of Cancer Care in Singapore. <i>Annals of Oncology</i> , 2019, 30, vi5.	0.6	0
93	A phase 1b study of <scp>OXIRI</scp> in pancreatic adenocarcinoma patients and its immunomodulatory effects. <i>International Journal of Cancer</i> , 2022, , .	2.3	0